Home
/

What is an LDL Cholesterol / Total Cholesterol Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

The LDL-C/Total Cholesterol ratio shows what fraction of your cholesterol rides in LDL particles—the atherogenic "delivery" lane—versus protective HDL and other pools. Most adults sit around 0.65–0.70; lower values are favorable (more HDL-bound cholesterol), while high ratios signal greater plaque-building risk and may suggest familial hypercholesterolemia in young people. This proportional index complements LDL-C and ApoB, offering insight into how cholesterol is distributed across lipoproteins.

Read more →
Table of contents

The share of cholesterol riding in LDL's delivery lane

LDL Cholesterol / Total Cholesterol (Mass Ratio) is the share of all cholesterol in your blood that is carried specifically by LDL particles. LDL cholesterol is the cholesterol packaged in low-density lipoproteins made by the liver as it remodels VLDL during normal fat transport. Total cholesterol is the sum of cholesterol contained in all circulating lipoproteins—mainly LDL, HDL, VLDL, and their intermediates. This blood test expresses that distribution as a simple proportion.

Why it matters: LDL's job is to deliver cholesterol to your tissues for cell membranes, hormones, and other needs (cholesterol delivery), while HDL and other pathways help return excess cholesterol to the liver (reverse cholesterol transport). The ratio shows how much of your circulating cholesterol sits in the LDL "delivery" lane versus the other carriers. In other words, it captures the balance of lipid traffic and the share residing in particles more prone to deposit cholesterol in artery walls (atherogenic burden). It provides a concise view of how cholesterol is partitioned across lipoproteins (lipoprotein cholesterol partitioning).

Why a proportion can flag risk a normal total cholesterol misses

LDL cholesterol/total cholesterol (mass ratio) shows what share of all circulating cholesterol is being carried by LDL particles—the lipoproteins most likely to penetrate artery walls and seed plaque. Because cholesterol transport touches the heart, brain, kidneys, and endocrine and immune systems, this proportion is a lens on whole‑body vascular health and metabolic signaling.

The LDL Cholesterol / Total Cholesterol (mass ratio) shows what fraction of your circulating cholesterol is carried in LDL particles. LDL delivers cholesterol to tissues for membranes and hormone synthesis; HDL and the liver clear it. This ratio summarizes the balance between delivery and clearance and is closely tied to atherosclerotic cardiovascular risk, with downstream effects on energy metabolism, cognition, and immune signaling.

Interpreting where your two-thirds falls

In most adults, the ratio sits roughly in the middle range, often around two‑thirds of total cholesterol. Values toward the lower end are generally considered more favorable, reflecting a distribution with relatively less LDL and more cholesterol in non‑LDL pools (especially HDL).

When the ratio is unusually low, it can simply reflect robust HDL levels and efficient reverse cholesterol transport, which is typically benign. Less commonly, it signals reduced LDL production or increased clearance, as can occur with hyperthyroid states, chronic inflammation, severe malabsorption, or advanced liver disease; people may notice weight loss, heat intolerance, fatigue, or easy bruising if an underlying condition is present. Children and premenopausal women tend to have lower ratios than adult men.

Low values usually reflect a smaller share of cholesterol in LDL. This can mean robust reverse transport (higher HDL) or simply lower LDL production/greater clearance, as seen with hyperthyroidism, acute illness, or liver dysfunction. A low ratio can also appear when triglyceride-rich lipoproteins are high, which lowers the percentage in LDL but does not necessarily lower risk.

Being in range suggests a balanced lipoprotein distribution and steady cholesterol trafficking to and from tissues. For cardiovascular protection, within reference ranges typically trends toward the lower end of the reference interval, provided triglycerides are not elevated.

When the ratio is high, a larger fraction of cholesterol rides on LDL, pointing to a more atherogenic profile. This is often silent for years while endothelial injury and plaque accumulate, eventually affecting the heart (angina), brain (TIA/stroke), kidneys, legs (claudication), or sexual function. Men and postmenopausal women more commonly show higher ratios; in pregnancy, lipids rise and the ratio may transiently increase. Markedly high values in youth suggest familial disorders and may be accompanied by tendon xanthomas.

High values usually reflect a larger share of cholesterol in LDL, indicating increased arterial exposure to atherogenic particles. This occurs with insulin resistance, too little thyroid hormone (hypothyroidism), reduced LDL receptor activity, nephrotic syndrome, cholestasis, or genetic elevations such as familial hypercholesterolemia or high lipoprotein(a). Ratios tend to be higher in men and rise after menopause; pregnancy raises LDL and can increase the ratio physiologically.

What can distort the ratio

Nonfasting samples and high triglycerides can alter calculated LDL and the ratio. Acute illness often lowers cholesterol. Lipoprotein(a) is included in LDL cholesterol. Medications that lower LDL reduce the ratio. ApoB and non-HDL cholesterol provide complementary risk information.

A complement to LDL-C, non-HDL-C, and ApoB

Big picture: this ratio complements LDL‑C, non‑HDL‑C, ApoB, and the total/HDL ratio, integrating liver output, thyroid and sex hormones, and insulin sensitivity. Over time, a lower proportion of cholesterol in LDL aligns with healthier arterial biology and reduced atherosclerotic risk.

FAQs

It measures the proportion of total cholesterol that is carried by LDL particles. The ratio is calculated as LDL-C divided by total cholesterol, expressed as a fraction or percentage.

It clarifies cardiovascular risk by showing how much of your cholesterol resides in LDL, adding nuance beyond total cholesterol alone.

Testing frequency depends on goals and change over time. Many people retest after 6–12 weeks of lifestyle or therapy adjustments and monitor periodically thereafter.

Dietary saturated fat, soluble fiber intake, weight change, physical activity, insulin resistance, triglyceride levels, and medications that alter LDL-C can shift the ratio.

This ratio uses values from a standard lipid panel. Fasting may be recommended for some panels to stabilize triglycerides, which can influence derived measures.

Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

References

  1. Millán, J., Pintó, X., Muñoz, A., Zúñiga, M., Rubiés-Prat, J., Pallardo, L. F., Masana, L., Mangas, A., Hernández-Mijares, A., González-Santos, P., Ascaso, J. F., & Pedro-Botet, J. (2009). Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vascular Health and Risk Management, 5, 757-765. https://pubmed.ncbi.nlm.nih.gov/19774217/
  2. Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M. R., ... Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
  3. Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019). Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiology, 4(12), 1287-1295. https://doi.org/10.1001/jamacardio.2019.3780
  4. Sampson, M., Ling, C., Sun, Q., Harb, R., Ashmaig, M., Warnick, R., Sethi, A., Fleming, J. K., Otvos, J. D., Meeusen, J. W., Delaney, S. R., Jaffe, A. S., Shamburek, R., Amar, M., & Remaley, A. T. (2020). A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiology, 5(5), 540-548. https://doi.org/10.1001/jamacardio.2020.0013
  5. Emerging Risk Factors Collaboration. (2009). Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 302(18), 1993-2000. https://doi.org/10.1001/jama.2009.1619

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey